collection
MENU ▼
Read by QxMD icon Read
search

Myeloma

shared collection
6 papers 0 to 25 followers
https://www.readbyqxmd.com/read/23364621/carfilzomib-in-multiple-myeloma-patients-with-renal-impairment-pharmacokinetics-and-safety
#1
A Z Badros, R Vij, T Martin, J A Zonder, L Kunkel, Z Wang, S Lee, A F Wong, R Niesvizky
This phase 2 study assessed the safety, pharmacokinetics, pharmacodynamics and efficacy of carfilzomib, a selective proteasome inhibitor, in patients with multiple myeloma and varying degrees of renal impairment, including patients on chronic hemodialysis. Patients were grouped by creatinine clearance: >80 ml/min, 50-80 ml/min, 30-49 ml/min, <30 ml/min and chronic hemodialysis. Carfilzomib was administered on days 1, 2, 8, 9, 15 and 16 in 28-day cycles: 15 mg/m(2) (Cycle 1), 20 mg/m(2) (Cycle 2) and 27 mg/m(2) (Cycles 3+)...
August 2013: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/29183887/how-i-manage-monoclonal-gammopathy-of-undetermined-significance
#2
REVIEW
Ronald S Go, S Vincent Rajkumar
Monoclonal gammopathy of undetermined significance (MGUS) is, in many ways, a unique hematologic entity. Unlike most hematologic conditions in which the diagnosis is intentional and credited to hematologists, the discovery of MGUS is most often incidental and made by nonhematologists. MGUS is considered an obligate precursor to several lymphoplasmacytic malignancies, including immunoglobulin light-chain amyloidosis, multiple myeloma, and Waldenström macroglobulinemia. Therefore, long-term follow-up is generally recommended...
January 11, 2018: Blood
https://www.readbyqxmd.com/read/29279102/a-question-of-class-treatment-options-for-patients-with-relapsed-and-or-refractory-multiple-myeloma
#3
REVIEW
Gordon Cook, Sonja Zweegman, María-Victoria Mateos, Florence Suzan, Philippe Moreau
Multiple classes of agent with distinct mechanisms of action are now available for the treatment of patients with relapsed and/or refractory multiple myeloma (RRMM), including immunomodulatory agents, proteasome inhibitors, histone deacetylase inhibitors and monoclonal antibodies. Additionally, several different drugs may be available within each agent class, each with their own specific efficacy and safety profile. This expansion of the treatment landscape has dramatically improved outcomes for patients. However, as the treatment options for RRMM become more complex, choosing the class of agent or combination of agents to use in the relapsed setting becomes increasingly challenging...
January 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/26997302/myeloma-bone-and-extra-medullary-disease-role-of-pet-ct-and-other-whole-body-imaging-techniques
#4
REVIEW
Giuseppe Rubini, Artor Niccoli-Asabella, Cristina Ferrari, Vito Racanelli, Nicola Maggialetti, Francesco Dammacco
Multiple myeloma (MM) is the second most common hematological malignancy. Although it can affect different organs, the bone compartment stands out both in terms of prevalence and clinical impact. Despite the striking advances in MM therapy, bone disease can remarkably affect the patient's quality of life. The occurrence and extension of bone marrow and extra-medullary involvement should be carefully assessed to confirm the diagnosis, to locate and whenever possible prevent dreadful complications such as pathological fractures and spinal cord compression, and to establish suitable therapeutic measures...
May 2016: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/26893241/a-practical-review-on-carfilzomib-in-multiple-myeloma
#5
REVIEW
Eli Muchtar, Morie A Gertz, Hila Magen
Carfilzomib, a second-generation proteasome inhibitor, has been increasingly used in relapsed/refractory multiple myeloma (MM) since its approval by the American food and drug administration (FDA) in the summer of 2012. The drug is active as a single agent and in combination with other antimyeloma agents. As a result of its efficacy and safety in the relapsed/refractory setting, carfilzomib is being evaluated in patients with newly diagnosed MM as well as in high-risk smoldering MM. This review will give a comprehensive summary of the drug, including its mechanism of action, the evaluated doses and schedules as well as a summary of the main clinical trials in the relapsed/refractory and newly diagnosed settings...
June 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/24801672/updates-to-the-guidelines-for-the-diagnosis-and-management-of-multiple-myeloma
#6
LETTER
Guy Pratt, Matthew Jenner, Roger Owen, John A Snowden, John Ashcroft, Kwee Yong, Sylvia Feyler, Gareth Morgan, Jamie Cavenagh, Gordon Cook, Eric Low, Simon Stern, Judith Behrens, Faith Davies, Jennifer Bird
No abstract text is available yet for this article.
October 2014: British Journal of Haematology
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"